Drug resistance of methicillin-resistant Staphylococcus aureus to mupirocin,fusidic acid and retapamulin

doi:10.3969/j.issn.1673-8640.2019.01.007

Abstract

Abstract:

Objective To investigate the drug resistance of methicillin-resistant Staphylococcus aureus （MRSA） to mupirocin,fusidic acid and retapamulin. Methods A total of 1 037 MRSA isolates were collected. The minimum inhibitory concentrations （MIC） of mupirocin,fusidic acid and retapamulin were determined by microbroth dilution method. The isolates resistant to 3 antibiotics were screened. The drug resistance of MRSA to mupirocin,fusidic acid and retapamulin was determined by Vitek 2 Compact analyzer. Results Among the 1 037 MRSA isolates,54 （5.2%） MRSA isolates were resistant to mupirocin,and 85.2% of them were high-level mupirocin resistance（MuH）. Among 9 （0.9%） fusidic acid resistant MRSA isolates,77.8% of them were low-level fusidic acid resistance（FAL）. The proportion of retapamulin resistant MRSA isolates was the lowest （0.2%）. The MRSA isolates,which were resistant to mupirocin,fusidic acid and retapamulin,were also highly resistant to aminoglycosides,macrolides,lincosamides and fluoroquinolones. Conclusions Low mupirocin,fusidic acid and retapamulin resistance in MRSA isolates is found. The existence of a small amount of drug resistant isolates suggests that it should strengthen the determination and surveillance of the drug resistance of Staphylococcus aureus.

Key words: Methicillin-resistant Staphylococcus aureus, Mupirocin, Fusidic acid, Retapamulin, Drug resistance

CLC Number:

R378.1

CHEN Wenjing, HE Chunyan, YANG Han, ZHAO Huanqiang, CUI Zelin, TANG Rong, LIU Qingzhong. Drug resistance of methicillin-resistant Staphylococcus aureus to mupirocin,fusidic acid and retapamulin[J]. Laboratory Medicine, 2019, 34(1): 33-37.

Figures/Tables 3

References 19

[1]	HETEM D J,BONTEN M J.Clinical relevance of mupirocin resistance in Staphylococcus aureus[J]. J Hosp Infect,2013,85(4):249-256.
[2]	MCNEIL J C,HULTEN K G,KAPLAN S L,et al.Decreased susceptibilities to retapamulin, mupirocin, and chlorhexidine among Staphylococcus aureus isolates causing skin and soft tissue infections in otherwise healthy children[J]. Antimicrob Agents Chemother,2014,58(5):2878-2883.
[3]	YU F,LIU Y,LU C,et al.Dissemination of fusidic acid resistance among Staphylococcus aureus clinical isolates[J]. BMC Microbiol,2015,15:210.
[4]	尚红,王毓三,申子瑜. 全国临床检验操作规程[M]. 4版. 北京:人民卫生出版社,2015:749.
[5]	Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing[S]. M100-S26,CLSI,2016.
[6]	LIU Q Z,WU Q,ZHANG Y B, et al.Prevalence of clinical meticillin-resistant Staphylococcus aureus (MRSA) with high-level mupirocin resistance in Shanghai and Wenzhou, China[J]. Int J Antimicrob Agents,2010,35(2):114-118.
[7]	TRACZEWSKI M M,BROWN S D.Proposed MIC and disk diffusion microbiological cutoffs and spectrum of activity of retapamulin, a novel topical antimicrobial agent[J]. Antimicrob Agents Chemother,2008,52(11):3863-3867.
[8]	SEPTIMUS E J,SCHWEIZER M L.Decolonization in prevention of health care-associated infections[J]. Clin Microbiol Rev,2016,29(2):201-222.
[9]	NAGANT C,DEPLANO A,NONHOFF C,et al.Low prevalence of mupirocin resistance in Belgian Staphylococcus aureus isolates collected during a 10 year nationwide surveillance[J]. J Antimicrob Chemother,2016,71(1):266-267.
[10]	严明,吴建国,黄文祥,等. 金黄色葡萄球菌对莫匹罗星和氯己定的耐药研究进展[J]. 中国感染与化疗杂志,2016,16(4):506-509.
[11]	HETEM D J,BONTEN M J.Clinical relevance of mupirocin resistance in Staphylococcus aureus[J]. J Hosp Infect,2013,85(4):249-256.
[12]	YANG J A,PARK D W,SOHN J W,et al.Molecular analysis of isoleucyl-tRNA synthetase mutations in clinical isolates of methicillin-resistant Staphylococcus aureus with low-level mupirocin resistance[J]. J Korean Med Sci,2006,21(5):827-832.
[13]	陈舒影,林纯婵,卢超慧,等. 金黄色葡萄球菌临床分离株对夫西地酸的耐药性分析[J]. 中国临床药理学杂志,2015,31(19):1971-1973.
[14]	CHEN H J,HUNG W C,TSENG S P,et al.Fusidic acid resistance determinants in Staphylococcus aureus clinical isolates[J]. Antimicrob Agents Chemother,2010,54(12):4985-4991.
[15]	李耘,薛峰,刘健,等. 夫西地酸体外抗菌活性研究[J]. 中国临床药理学杂志,2013,29(1):34-37.
[16]	SARAVOLATZ L D,PAWLAK J,SARAVOLATZ S N,et al.In vitro activity of retapamulin against Staphylococcus aureus resistant to various antimicrobial agents[J]. Antimicrob Agents Chemother,2013,57(9):4547-4550.
[17]	PÉREZ-TRALLERO E,TAMAYO E,MONTES M,et al. In vitro activities of retapamulin and 16 other antimicrobial agents against recently obtained Streptococcus pyogenes isolates[J]. Antimicrob Agents Chemother,2011,55(5):2406-2408.
[18]	HARRINGTON A T,BLACK J A,CLARRIDGE J E 3rd. In vitro activity of retapamulin and antimicrobial susceptibility patterns in a longitudinal collection of methicillin-resistant Staphylococcus aureus isolates from a veterans affairs medical center[J]. Antimicrob Agents Chemother,2015,60(3):1298-1303.
[19]	WOODFORD N,AFZAL-SHAH M,WARNER M,et al.In vitro activity of retapamulin against Staphylococcus aureus isolates resistant to fusidic acid and mupirocin[J]. J Antimicrob Chemother,2008,62(4):766-768.

抗菌药物	MIC（μg/mL）	菌株数[株（%）]	耐药情况
莫匹罗星	<8	983（94.8）	S
	8	1（0.1）	MuL
	32	2（0.2）	MuL
	64	1（0.1）	MuL
	128	3（0.3）	MuL
	256	1（0.1）	MuL
	512	8（0.8）	MuH
	≥1 024	38（3.7）	MuH
夫西地酸	≤1	1 028（99.1）	S
	2	5（0.5）	MAL
	4	4（0.4）	MAL
	128	2（0.2）	FAH
瑞他莫林	<1	1 035（99.8）	S
	1	1（0.1）	R
	8	1（0.1）	R

抗菌药物	MIC（μg/mL）	菌株数[株（%）]	耐药情况
莫匹罗星	<8	983（94.8）	S
	8	1（0.1）	MuL
	32	2（0.2）	MuL
	64	1（0.1）	MuL
	128	3（0.3）	MuL
	256	1（0.1）	MuL
	512	8（0.8）	MuH
	≥1 024	38（3.7）	MuH
夫西地酸	≤1	1 028（99.1）	S
	2	5（0.5）	MAL
	4	4（0.4）	MAL
	128	2（0.2）	FAH
瑞他莫林	<1	1 035（99.8）	S
	1	1（0.1）	R
	8	1（0.1）	R

抗菌药物	莫匹罗星耐药MRSA				夫西地酸耐药MRSA				瑞他莫林耐药MRSA 总耐药率（2株）
抗菌药物	总耐药率（54株）	MuH （46株）	MuL （8株）	P值^*	总耐药率（9株）	FAH （2株）	FAL （7株）	P值^#	瑞他莫林耐药MRSA 总耐药率（2株）
庆大霉素	83.33	86.96	62.50	0.118	44.44	50.00	42.86	1.000	100.00
四环素	92.59	93.48	87.50	0.484	44.44	100.00	28.57	0.167	100.00
克林霉素	92.59	91.30	100.00	1.000	55.56	100.00	42.86	0.444	100.00
红霉素	94.44	93.48	100.00	1.000	88.89	100.00	85.71	1.000	100.00
环丙沙星	92.59	93.48	87.50	0.484	66.67	100.00	57.14	0.500	100.00
左氧氟沙星	96.30	95.65	100.00	1.000	66.67	100.00	57.14	0.500	100.00
莫西沙星	94.44	95.65	87.50	0.388	55.56	100.00	42.86	0.444	100.00
复方磺胺甲噁唑	5.56	4.35	12.50	0.388	0.00	0.00	0.00		0.00
利福平	1.85	2.17	0.00	1.000	11.11	0.00	14.29	1.000	0.00
呋喃妥因	0.00	0.00	0.00		0.00	0.00	0.00		0.00
利奈唑胺	0.00	0.00	0.00		0.00	0.00	0.00		0.00
万古霉素	0.00	0.00	0.00		0.00	0.00	0.00		0.00

抗菌药物	莫匹罗星耐药MRSA				夫西地酸耐药MRSA				瑞他莫林耐药MRSA 总耐药率（2株）
抗菌药物	总耐药率（54株）	MuH （46株）	MuL （8株）	P值^*	总耐药率（9株）	FAH （2株）	FAL （7株）	P值^#	瑞他莫林耐药MRSA 总耐药率（2株）
庆大霉素	83.33	86.96	62.50	0.118	44.44	50.00	42.86	1.000	100.00
四环素	92.59	93.48	87.50	0.484	44.44	100.00	28.57	0.167	100.00
克林霉素	92.59	91.30	100.00	1.000	55.56	100.00	42.86	0.444	100.00
红霉素	94.44	93.48	100.00	1.000	88.89	100.00	85.71	1.000	100.00
环丙沙星	92.59	93.48	87.50	0.484	66.67	100.00	57.14	0.500	100.00
左氧氟沙星	96.30	95.65	100.00	1.000	66.67	100.00	57.14	0.500	100.00
莫西沙星	94.44	95.65	87.50	0.388	55.56	100.00	42.86	0.444	100.00
复方磺胺甲噁唑	5.56	4.35	12.50	0.388	0.00	0.00	0.00		0.00
利福平	1.85	2.17	0.00	1.000	11.11	0.00	14.29	1.000	0.00
呋喃妥因	0.00	0.00	0.00		0.00	0.00	0.00		0.00
利奈唑胺	0.00	0.00	0.00		0.00	0.00	0.00		0.00
万古霉素	0.00	0.00	0.00		0.00	0.00	0.00		0.00